AssetCX unlocks on-chain yield for custodied assets.
By combining our vault infrastructure with qualified custodians like @BitGo, AssetCX creates an entirely new path to make digital assets productive.
Made possible only by @ConcreteXYZ.
Every cell in our body carries genes that carefully regulate its growth and trigger cell death when something goes wrong. These built-in safeguards prevent damaged or abnormal cells from multiplying uncontrollably. However, cancer cells find ways to bypass these natural defenses.
One of the mechanisms they use involves proteins called Histone Deacetylases (HDACs), which can switch off genes responsible for controlling cell growth and initiating cancer cell death. Among them, HDAC3 plays a critical role in helping cancer cells survive, proliferate, and even resist existing therapies. While several HDAC inhibitor drugs are already available, most target multiple HDAC proteins simultaneously, often causing unwanted side effects by affecting healthy cells.
Supported by BFI-BIOME, Prof. Balaram Ghosh and his team at BITS Pilani Hyderabad Campus are developing AH22, a novel and highly selective HDAC3 inhibitor designed to precisely reactivate the body’s natural cancer-suppressing genes. By selectively blocking HDAC3, AH22 aims to restore the cell’s ability to eliminate cancer cells while minimizing damage to healthy tissues.
The team is now advancing AH22 through preclinical translation, generating the critical safety and efficacy data needed before it can enter human clinical trials. If successful, this targeted therapy could pave the way for safer, more effective cancer treatments that overcome drug resistance and improve outcomes for patients.
BFI Innovation Full Stack brings prototyping, clinical validation, large scale field studies, and market access onto one platform, with structured support at every stage, and room for innovators to join at any point in their journey, from prototyping to near market readiness.
Deadline's approaching, don't wait to apply.
Application deadline for Cohort 1: 31 July 2026
Apply now via Interconnect: https://t.co/XTLtMPGtLM
Learn more: https://t.co/FoKKWoLcnE
@GITAMUniversity@NimsUniversity@iiscbangalore@bitspilaniindia@IGIBSocial@AIC_CCMB@iitbombay@aiims_newdelhi@AshokaUniv@THSTIFaridabad
The best conversations begin with great questions.
Have a question about biosciences, digital health, healthcare innovation, or the future of research? Share it with us for the upcoming Science.Unblocked Podcast featuring Dr. Anurag Agrawal, hosted by Dr. Gaurav Singh.
Submit your question using the QR code or via: https://t.co/wlQY0nGp2a
🚀 GXT Presale – Stage 2 is LIVE!
Buy $GXT at just $0.15 before the planned listing price of $0.60.
🔥 Limited allocation: Only 3M GXT available in Stage 2 - already 32% sold.
👉 Buy now: https://t.co/XELdRklHd7
#GXT#GXTExchange#Presale#Crypto#Web3#TokenSale#Altcoin #CryptoLaunch